GLOBAL SETTLEMENT AGREEMENT REACHED IN TUSCHL PATENTS LITIGATION
March 16, 2011
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the signing of a global settlement agreement among Alnylam, Max Planck Society ("Max Planck"), the Whitehead Institute for Biomedical Research ("Whitehead") and the University of Massachusetts ("UMass") resolving their ongoing litigation regarding the Tuschl patents.
Full Story Below
Rapid Response
Free Case Evaluation
The Help You Need,
When You Need it Most
More from Settlement News Directory
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
